Dr Alessandra Francesconi , one of the clinical investigators for the program , will be presenting the poster in the Developmental Therapeutics - Vascular Targeting poster session on Saturday 30th May from 8 : 00 AM to 12 : 00 PM ( US EST ) , Level 2 , West Hall C. The poster entitled " Phase I evaluation of orally-administered CYT997 , a novel cytotoxic vascular-disrupting agent , in patients with advanced cancer " details safety , tolerability and preliminary activity findings from this study , which concluded in February 2009 . CYT997 is currently undergoing further clinical investigation in Phase II studies in relapsed glioblastoma multiforme and multiple myeloma .